Communication Affichée: Poster Tour 3


Le 15/10/2021 de 13:30 à 14:00


Retour Session

P080

Durée de l'effet du traitement par IncobotulinumtoxinA (Xeomin®) dans la spasticité du membre supérieur

Laetitia Thibault (, )

Objective : The efficacy and safety of incobotulinumtoxinA ≤400 U was demonstrated in subjects with post-stroke upper-limb spasticity in a randomized, double-blind Phase 3 study with an open-label extension (OLEX; EudraCT number 2005-003951-11, NCT00432666). We report a post-hoc analysis of the duration of the treatment effect.

Keywords : duration of effect; incobotulinumtoxinA; post-stroke; upper-limb spasticity; treatment interval